

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
 Stylesheet Version v1.2

EPAS ID: PAT3463419

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
EPISOURCE SA	12/15/2004
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	DFB PHARMACEUTICALS, INC.
<b>Street Address:</b>	3909 HULEN STREET
<b>City:</b>	FORT WORTH
<b>State/Country:</b>	TEXAS
<b>Postal Code:</b>	76107
<b>PROPERTY NUMBERS Total: 6</b>	
<b>Property Type</b>	<b>Number</b>
Application Number:	13659378
Application Number:	13368706
Application Number:	12967619
Application Number:	12562767
Application Number:	12255481
Application Number:	10526853
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	(512)536-4598
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Phone:</b>	5124745201
<b>Email:</b>	aoipdocket@nortonrosefulbright.com
<b>Correspondent Name:</b>	NORTON ROSE FULBRIGHT US LLP
<b>Address Line 1:</b>	SAN JACINTO BLVD.
<b>Address Line 2:</b>	SUITE 1100
<b>Address Line 4:</b>	AUSTIN, TEXAS 78701
<b>ATTORNEY DOCKET NUMBER:</b>	DFBP.P0010US1-C6
<b>NAME OF SUBMITTER:</b>	SCOTT RICHARD
<b>SIGNATURE:</b>	/Scott Richard/
<b>DATE SIGNED:</b>	07/30/2015

**Total Attachments: 7**

source=DFBP10assign3#page1.tif

source=DFBP10assign3#page2.tif

source=DFBP10assign3#page3.tif

source=DFBP10assign3#page4.tif

source=DFBP10assign3#page5.tif

source=DFBP10assign3#page6.tif

source=DFBP10assign3#page7.tif

**PATENT**

**REEL: 036220 FRAME: 0554**

Express Mail Label No.: EV475167504US  
Date of Deposit: February 16, 2005

Attorney Docket No.: 17811-999

## ASSIGNMENT

**EpiSource SA**, a corporation organized under the laws of **Switzerland**, having principal offices at 1 Rue de Sébeillon, 1004 Lausanne, **Switzerland** ("the ASSIGNOR"), the undersigned, for good and valuable consideration, the receipt of which is hereby acknowledged, hereby assigns, sells and transfers to **DFB Pharmaceuticals, Inc.**, a corporation organized under the laws of **Texas**, having principal offices at 3909 Hulen Street, Fort Worth, Texas 76107, and its successors, assigns and legal representatives, all hereinafter referred to as the ASSIGNEE:

(1) the entire right, title and interest for the United States and in all countries, in and to any and all inventions, discoveries and applications which are disclosed in the patents and applications for patents as listed in Schedule A, including any renewals, revivals, reissues, reexaminations, extensions, continuations and divisions thereof and any substitute applications therefor; (2) the full and complete right to file patent applications in the name of the ASSIGNEE, its designee, or in the name of EpiSource SA at the ASSIGNEE, or its designee's election, on the aforesaid inventions, discoveries and applications in all countries of the world; (3) the entire right, title and interest in and to any Letters Patents which may issue thereon in the United States or in any country, and any renewals, revivals, reissues, reexaminations and extensions thereof, and any patents of confirmation, registration and importation of the same; and (4) the entire right, title and interest in all Convention and Treaty Rights of all kinds thereon, including without limitation all rights of priority in any country of the world, in and to the above inventions, discoveries and applications.

EpiSource SA hereby authorizes and requests the competent authorities to grant and to issue any and all such Letters Patent in the United States and throughout the world to the ASSIGNEE of the entire right, title and interest therein, as fully and entirely as the same would have been held and enjoyed by EpiSource SA had this assignment, sale and transfer not been made.

EpiSource SA agrees, at any time, upon the request of the ASSIGNEE, to execute and to deliver to the ASSIGNEE any additional applications for patents for said inventions and discoveries, or any part or parts thereof, and any applications for patents of confirmation, registration and importation based on any Letters Patent issuing on said inventions, discoveries, or applications and divisions, continuations, renewals, revivals, reissues, reexaminations and extensions thereof.


EpiSource SA further agrees at any time to execute and to deliver upon request of the ASSIGNEE such additional documents, if any, as are necessary or desirable to secure patent protection on said inventions, discoveries and applications throughout all countries of the world, and otherwise to do the necessary to give full effect to and to perfect the rights of the ASSIGNEE under this Assignment, including the execution, delivery and procurement of any and all further documents evidencing this assignment, transfer and sale as may be necessary or desirable.

EpiSource SA hereby covenants that no assignment, sale, agreement or encumbrance has been or will be made or entered into which would conflict with this assignment.


EpiSource SA further covenants that ASSIGNEE will, upon its request, be provided promptly with all pertinent facts and documents relating to said invention and said Letters Patent and legal equivalents as may be known and accessible to ASSIGNOR and will testify as to the same in any interference, litigation or proceeding related thereto and will promptly execute and deliver to ASSIGNEE or its legal representatives any and all papers, instruments or affidavits required to apply for, obtain, maintain, issue and enforce said application, said invention and said Letters Patent and said equivalents thereof which may be necessary or desirable to carry out the purposes thereof.

For EpiSource SA:

Date: December 15, 2004


  
Signature of:  
Title: Director  
EpiSource SA

IN WITNESS WHEREOF,

  
Signature of witness:

this 15<sup>th</sup> day of December 2004  
Date of signing

IN WITNESS WHEREOF,

  
Signature of witness:

this 15<sup>th</sup> day of DECEMBER, 2004  
Date of signing

**For DFB Pharmaceuticals, Inc.:**

Date:

*Good Start*  
Signature of:  
Title: *Chief Scientific Officer*  
DFB Pharmaceuticals, Inc.

IN WITNESS WHEREOF,

*Nat. Song*  
Signature of witness:

this 15<sup>th</sup> day of December 2004  
Date of signing

IN WITNESS WHEREOF,

*[Signature]*  
Signature of witness:

this 15<sup>th</sup> day of December 2004  
Date of signing

**SCHEDULE A**

1. 17811-014-004 (M-14 AU)  
Australian Patent Application No. 60098/00  
Entitled: "Improved Keratinocyte Culture and Uses Thereof"
2. 17811-014-008 (M-14 CA)  
Canadian Patent Application No. 2,379,949  
Entitled: "Improved Keratinocyte Culture and Uses Thereof"
3. 17811-014-019 (M-14 EP)  
European Patent Application No. 00946228.4  
Entitled: "Improved Keratinocyte Culture and Uses Thereof"
4. 17811-014-032 (M-14 JP)  
Japanese Patent Application No. 2001-511156  
Entitled: "Improved Keratinocyte Culture and Uses Thereof"
5. 17811-014-061 (M-14 WO)  
PCT Patent Application No. PCT/IB00/01076  
Entitled: "Improved Keratinocyte Culture and Uses Thereof"
6. 17811-014 (M-14)  
United States Patent No. 6,548,058  
Entitled: "Keratinocyte Culture and Uses Thereof"
7. 17811-014 CIP (M-14 CIP)  
United States Patent No. 6,730,513  
Entitled: "Keratinocyte Culture and Uses Thereof"

8. 17811-014 NATL (M-14 NATL)  
United States Patent Application No. 10/031,188  
Entitled: "Improved Keratinocyte Culture and Uses Thereof"
9. 17811-015 (M-15)  
United States Patent No. 5,968,546  
Entitled: "Keratinocyte Culture from Precursor Cells"
10. 17811-017 (M-17)  
United States Patent No. 6,673,603  
Entitled: "Cell Paste Comprising Keratinocytes and Fibroblasts"
11. 17811-017 CIP (M-17 CIP)  
United States Patent Application No. 10/324,257  
Entitled: "Methods and Compositions for Tissue Regeneration"
12. 17811-017-032 CIP (M-17 CIP JP)  
Japanese Patent Application No. 2003-157362  
Entitled: "Methods and Compositions for Tissue Regeneration"
13. 17811-017-061 CIP (M-17 CIP WO)  
PCT Patent Application No. PCT/US03/27888  
Entitled: "Methods and Compositions for Tissue Regeneration"
14. 17811-017-004 (M-17 AU)  
Australian Patent Application No. 2001286952  
Entitled: "Methods and Compositions for Tissue Regeneration"
15. 17811-017-008 (M-17 CA)  
Canadian Patent Application No. 2426107  
Entitled: "Methods and Compositions for Tissue Regeneration"



16. 17811-017-019 (M-17 EP)  
European Patent Application No. 01966441.6  
Entitled: "Methods and Compositions for Tissue Regeneration"
17. 17811-017-061 (M-17 WO)  
PCT Patent Application No. PCT/US01/27104  
Entitled: "Methods and Compositions for Tissue Regeneration"
18. 17811-028 (M-28)  
United States Patent Application No. 10/655,435  
Entitled: "Fibrin Cell Supports and Methods of Use Thereof"
19. 17811-028-061 (M-28 WO)  
PCT Patent Application No. PCT/IB03/04506  
Entitled: "Fibrin Cell Supports and Methods of Use Thereof"